231 related articles for article (PubMed ID: 35556126)
21. The Genetic Duet of
Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
[No Abstract] [Full Text] [Related]
22. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
23. Effect of BRAF
Mu ZZ; Zhang YQ; Sun D; Lu T; Lin YS
Endocr Pract; 2022 Mar; 28(3):265-270. PubMed ID: 34890787
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of a cohort of 271 patients with lung metastases from differentiated thyroid carcinoma.
Maciel J; Cavaco D; Silvestre C; Simões Pereira J; Vilar H; Leite V
Clin Endocrinol (Oxf); 2022 Dec; 97(6):814-821. PubMed ID: 35192239
[TBL] [Abstract][Full Text] [Related]
25. Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes.
Simões-Pereira J; Saramago A; Rodrigues R; Pojo M; Pires C; Horta M; López-Presa D; Rito M; Cabrera R; Ferreira TC; Leite V; Cavaco BM
Endocrine; 2024 May; 84(2):625-634. PubMed ID: 38102497
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
27. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER AND DISTANT METASTASES.
Hirsch D; Levy S; Tsvetov G; Gorshtein A; Slutzky-Shraga I; Akirov A; Robenshtok E; Shimon I; Benbassat CA
Endocr Pract; 2017 Oct; 23(10):1193-1200. PubMed ID: 28704099
[TBL] [Abstract][Full Text] [Related]
28. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
29. PANCREAS METASTASES FROM PAPILLARY THYROID CARCINOMA: A REVIEW OF THE LITERATURE.
Davidson M; Olsen RJ; Ewton AA; Robbins RJ
Endocr Pract; 2017 Dec; 23(12):1425-1429. PubMed ID: 29144798
[TBL] [Abstract][Full Text] [Related]
30. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050
[TBL] [Abstract][Full Text] [Related]
31. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
[TBL] [Abstract][Full Text] [Related]
32. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
33. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
34. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases.
Mihailovic J; Stefanovic L; Malesevic M; Markoski B
Thyroid; 2009 Mar; 19(3):227-32. PubMed ID: 19265493
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract][Full Text] [Related]
36. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
37. APOBEC SBS13 Mutational Signature-A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma.
Siraj S; Masoodi T; Siraj AK; Azam S; Qadri Z; Parvathareddy SK; Bu R; Siddiqui KS; Al-Sobhi SS; AlDawish M; Al-Kuraya KS
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326735
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
[TBL] [Abstract][Full Text] [Related]
39. Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape.
Nies M; Vassilopoulou-Sellin R; Bassett RL; Yedururi S; Zafereo ME; Cabanillas ME; Sherman SI; Links TP; Waguespack SG
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1683-e1697. PubMed ID: 33382403
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
